Literature DB >> 16051814

Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

B Poon1, J F Hsu, V Gudeman, I S Y Chen, K Grovit-Ferbas.   

Abstract

The lack of success of subunit human immunodeficiency virus (HIV) type 1 vaccines to date suggests that multiple components or a complex virion structure may be required. We hypothesized that the failure of current vaccine strategies to induce protective antibodies is linked to the inability of native envelope structures to readily elicit these types of antibodies. We have previously reported on the ability of a formaldehyde-treated, heat-inactivated vaccine to induce modest antibody responses in animal vaccine models. We investigated here whether immunization for HIV with an envelope-modified, formaldehyde-stabilized, heat-inactivated virion vaccine could produce higher-titer and/or broader neutralizing antibody responses. Thus, a clade B vaccine which contains a single point mutation in gp41 (Y706C) that results in increased incorporation of oligomeric Env into virions was constructed. This vaccine was capable of inducing high-titer antibodies that could neutralize heterologous viruses, including those of clades A and C. These results further support the development of HIV vaccines with modifications in native Env structures for the induction of neutralizing antibody responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051814      PMCID: PMC1182614          DOI: 10.1128/JVI.79.16.10210-10217.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

2.  Mechanism(s) of FIV vaccine protection.

Authors:  R Pu; M C Tellier; J K Yamamoto
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

3.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines.

Authors:  M C Tellier; J Soos; R Pu; D Pollock; J K Yamamoto
Journal:  Vet Microbiol       Date:  1997-06-30       Impact factor: 3.293

5.  Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response.

Authors:  S A Jeffs; C Shotton; P Balfe; J A McKeating
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

6.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.

Authors:  B Chackerian; E M Long; P A Luciw; J Overbaugh
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.

Authors:  Miriam I Quiñones-Kochs; Linda Buonocore; John K Rose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  J R Mascola; S W Snyder; O S Weislow; S M Belay; R B Belshe; D H Schwartz; M L Clements; R Dolin; B S Graham; G J Gorse; M C Keefer; M J McElrath; M C Walker; K F Wagner; J G McNeil; F E McCutchan; D S Burke
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.

Authors:  M A Egan; L M Carruth; J F Rowell; X Yu; R F Siliciano
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface.

Authors:  M M Sauter; A Pelchen-Matthews; R Bron; M Marsh; C C LaBranche; P J Vance; J Romano; B S Haggarty; T K Hart; W M Lee; J A Hoxie
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

View more
  19 in total

1.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

Review 2.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

3.  Evaluation of lumazine synthase from Bacillus anthracis as a presentation platform for polyvalent antigen display.

Authors:  Yangjie Wei; Newton Wahome; Greta VanSlyke; Neal Whitaker; Prashant Kumar; Michael L Barta; Wendy L Picking; David B Volkin; Nicholas J Mantis; C Russell Middaugh
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

4.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.

Authors:  Eri Nakatani-Webster; Shiu-Lok Hu; William M Atkins; Carlos Enrique Catalano
Journal:  J Virol Methods       Date:  2015-09-28       Impact factor: 2.014

6.  Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection.

Authors:  Dong Sung An; Betty Poon; Raphael Ho Tsong Fang; Kees Weijer; Bianca Blom; Hergen Spits; Irvin S Y Chen; Christel H Uittenbogaart
Journal:  Clin Vaccine Immunol       Date:  2007-02-21

Review 7.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

8.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Authors:  Emma T Crooks; Penny L Moore; Michael Franti; Charmagne S Cayanan; Ping Zhu; Pengfei Jiang; Robbert P de Vries; Cheryl Wiley; Irina Zharkikh; Norbert Schülke; Kenneth H Roux; David C Montefiori; Dennis R Burton; James M Binley
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

9.  Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice.

Authors:  Thomas D Norton; Anjie Zhen; Takuya Tada; Jennifer Kim; Scott Kitchen; Nathaniel R Landau
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

10.  Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Authors:  Daniel P Leaman; Armando Stano; Yajing Chen; Lei Zhang; Michael B Zwick
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.